Takeda Pharmaceutical Company Limited TAK

$ 14.09 0.93%

Quarterly report 2022-Q1
added 06-29-2022

Takeda Pharmaceutical Company Limited Balance Sheet 2011-2024 | TAK

Annual Balance Sheet Takeda Pharmaceutical Company Limited

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	4.46 T	5.05 T	691 B	825 B	317 B	77.2 B	194 B	252 B	108 B	-201 B
Long Term Debt	-	4.51 T	4.77 T	986 B	600 B	540 B	629 B	705 B	540 B	318 B	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	5.96 T	5.92 T	6.2 T	1.35 T	1.04 T	956 B	1.07 T	1.23 T	1.12 T	753 B	213 B
Total Current Liabilities	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	7.74 T	8.09 T	8.71 T	2.09 T	2.41 T	1.81 T	2.09 T	2.03 T	1.73 T	1.51 T	650 B
Deferred Revenue	-	682 B	-	-	-	-	-	-	-	-	-
Retained Earnings	1.51 T	1.37 T	1.57 T	1.56 T	1.51 T	1.52 T	1.6 T	1.9 T	2.24 T	2.25 T	2.27 T
Total Assets	12.9 T	12.8 T	13.9 T	4.11 T	4.36 T	3.82 T	4.3 T	4.57 T	3.96 T	3.58 T	2.79 T
Cash and Cash Equivalents	966 B	638 B	702 B	295 B	319 B	-	-	-	-	-	-
Book Value	5.18 T	4.73 T	5.16 T	2.02 T	1.95 T	2.01 T	2.21 T	2.54 T	2.22 T	2.07 T	2.14 T
Total Shareholders Equity	5.18 T	4.73 T	5.19 T	2.02 T	1.95 T	-	-	-	-	-	-

All numbers in JPY currency

Quarterly Balance Sheet Takeda Pharmaceutical Company Limited

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	5.35 T	-	-	-	5.96 T	-	-	-	5.92 T	-	-	-	6.05 T	-	-	-	1.35 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	7.49 T	-	-	-	7.74 T	-	-	-	8.09 T	-	-	-	8.61 T	-	-	-	2.09 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	1.48 T	-	-	-	1.51 T	-	-	-	1.37 T	-	-	-	1.6 T	-	-	-	1.56 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	13.2 T	-	-	-	12.9 T	-	-	-	12.8 T	-	-	-	13.8 T	-	-	-	4.11 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	850 B	-	-	-	966 B	-	-	-	638 B	-	-	-	702 B	-	-	-	295 B	-	-	-	319 B	-	-	-	451 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	5.68 T	-	-	-	5.18 T	-	-	-	4.73 T	-	-	-	5.19 T	-	-	-	2.02 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	5.68 T	-	-	-	5.18 T	-	-	-	4.73 T	-	-	-	5.19 T	-	-	-	2.02 T	-	-	-	1.95 T	-	-	-	2.01 T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in JPY currency